Findings of Research Misconduct, 23282 [2018-10592]
Download as PDF
<![CDATA[
23282
Federal Register / Vol. 83, No. 97 / Friday, May 18, 2018 / Notices
clearance. For U.S. citizens, please
RSVP no later than Monday, June 25,
2018. Written comments are welcome
and encouraged, even if you are
planning to attend in person. Please
send them to the email address:
us.who.irhp@hhs.gov.
Dated: May 9, 2018.
G. Garrett Grigsby,
Director for Global Affairs.
[FR Doc. 2018–10634 Filed 5–17–18; 8:45 am]
BILLING CODE 4150–38–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Findings of Research Misconduct
Office of the Secretary, HHS.
ACTION: Notice.
AGENCY:
Findings of research
misconduct have been made on the part
of Maria Cristina Miron Elqutub,
Research Interviewer, University of
Texas MD Anderson Cancer Center
(MDACC). Dr. Elqutub engaged in
research misconduct in research
supported by National Institute of
Dental and Craniofacial Research
(NIDCR), National Institutes of Health
(NIH), grant U01 DE019765–01. The
administrative actions, including three
(3) years of supervision, were
implemented beginning on April 26,
2018, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Maria Cristina Miron Elqutub,
University of Texas MD Anderson
Cancer Center: Based on Respondent’s
admission, the report of an inquiry
conducted by MDACC, and analysis
conducted by ORI in its oversight
review, ORI found that Ms. Maria
Cristina Miron Elqutub, Research
Interviewer, MDACC, engaged in
research misconduct in research
supported by NIDCR, NIH, grant U01
DE019765–01.
ORI found that Respondent engaged
in research misconduct by intentionally
and knowingly falsifying and/or
fabricating data that were included in
the following two (2) published papers
and two (2) grant progress reports
submitted to NIDCR, NIH:
• PLoS One 10(6):e0128753, 2015 Jun
2 (hereafter referred to as ‘‘PLoS One
2015’’).
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:38 May 17, 2018
Jkt 244001
• Cancer 121(14):2367–74, 2015 Jul
15 (hereafter referred to as ‘‘Cancer
2015’’) Retracted in: Cancer 124(4):869,
2018 Feb 15.
• 5 U01 DE019765–04.
• 5 U01 DE019765–05.
Specifically, ORI found that
Respondent engaged in research
misconduct by recording dates and
providing her own blood samples to
cause these samples to be falsely labeled
as samples from ninety-eight (98) study
subjects in a cancer genetics study
involving human blood samples. This
resulted in the reporting of false data in
Tables 1, 2, 3, and 4 in PLoS One 2015,
in Figure 1 and Tables 1, 2, 3, and 4 in
Cancer 2015, and in the Results sections
of Project 2 progress reports for NIDCR,
NIH, grants 5 U01 DE019765–04 and 5
U01 DE019765–05.
Ms. Elqutub entered into a Voluntary
Settlement Agreement and voluntarily
agreed, beginning on April 26, 2018:
(1) To have her research supervised
for a period of three (3) years;
Respondent agreed to ensure that prior
to the submission of an application for
U.S. Public Health Service (PHS)
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, the institution employing her
must submit a plan for supervision of
Respondent’s duties to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that she will not
participate in any PHS-supported
research until a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that for a period of three (3) years,
any institution employing her must
submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) if no supervisory plan is provided
to ORI, to provide certification to ORI
on an annual basis for a period of three
(3) years that she has not engaged in,
applied for, or had her name included
on any application, proposal, or other
request for PHS funds without prior
notification to ORI;
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
(4) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years;
and
(5) to the correction or retraction of
PLoS One 10(6):e0128753, 2015 Jun 2.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–10592 Filed 5–17–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Social Sciences and Population Studies A
Study Section.
Date: June 6, 2018.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave. NW, Washington, DC 20037.
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Development—1
Study Section.
Date: June 12, 2018.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Thomas Beres, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7840, Bethesda, MD 20892, 301–435–
1175, berestm@mail.nih.gov.
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 83, Number 97 (Friday, May 18, 2018)]
[Notices]
[Page 23282]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10592]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made on the part of
Maria Cristina Miron Elqutub, Research Interviewer, University of Texas
MD Anderson Cancer Center (MDACC). Dr. Elqutub engaged in research
misconduct in research supported by National Institute of Dental and
Craniofacial Research (NIDCR), National Institutes of Health (NIH),
grant U01 DE019765-01. The administrative actions, including three (3)
years of supervision, were implemented beginning on April 26, 2018, and
are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Maria Cristina Miron Elqutub, University of Texas MD Anderson
Cancer Center: Based on Respondent's admission, the report of an
inquiry conducted by MDACC, and analysis conducted by ORI in its
oversight review, ORI found that Ms. Maria Cristina Miron Elqutub,
Research Interviewer, MDACC, engaged in research misconduct in research
supported by NIDCR, NIH, grant U01 DE019765-01.
ORI found that Respondent engaged in research misconduct by
intentionally and knowingly falsifying and/or fabricating data that
were included in the following two (2) published papers and two (2)
grant progress reports submitted to NIDCR, NIH:
PLoS One 10(6):e0128753, 2015 Jun 2 (hereafter referred to
as ``PLoS One 2015'').
Cancer 121(14):2367-74, 2015 Jul 15 (hereafter referred to
as ``Cancer 2015'') Retracted in: Cancer 124(4):869, 2018 Feb 15.
5 U01 DE019765-04.
5 U01 DE019765-05.
Specifically, ORI found that Respondent engaged in research
misconduct by recording dates and providing her own blood samples to
cause these samples to be falsely labeled as samples from ninety-eight
(98) study subjects in a cancer genetics study involving human blood
samples. This resulted in the reporting of false data in Tables 1, 2,
3, and 4 in PLoS One 2015, in Figure 1 and Tables 1, 2, 3, and 4 in
Cancer 2015, and in the Results sections of Project 2 progress reports
for NIDCR, NIH, grants 5 U01 DE019765-04 and 5 U01 DE019765-05.
Ms. Elqutub entered into a Voluntary Settlement Agreement and
voluntarily agreed, beginning on April 26, 2018:
(1) To have her research supervised for a period of three (3)
years; Respondent agreed to ensure that prior to the submission of an
application for U.S. Public Health Service (PHS) support for a research
project on which Respondent's participation is proposed and prior to
Respondent's participation in any capacity on PHS-supported research,
the institution employing her must submit a plan for supervision of
Respondent's duties to ORI for approval; the supervision plan must be
designed to ensure the scientific integrity of Respondent's research
contribution; Respondent agreed that she will not participate in any
PHS-supported research until a supervision plan is submitted to and
approved by ORI; Respondent agreed to maintain responsibility for
compliance with the agreed upon supervision plan;
(2) that for a period of three (3) years, any institution employing
her must submit, in conjunction with each application for PHS funds, or
report, manuscript, or abstract involving PHS-supported research in
which Respondent is involved, a certification to ORI that the data
provided by Respondent are based on actual experiments or are otherwise
legitimately derived and that the data, procedures, and methodology are
accurately reported in the application, report, manuscript, or
abstract;
(3) if no supervisory plan is provided to ORI, to provide
certification to ORI on an annual basis for a period of three (3) years
that she has not engaged in, applied for, or had her name included on
any application, proposal, or other request for PHS funds without prior
notification to ORI;
(4) to exclude herself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of three (3) years; and
(5) to the correction or retraction of PLoS One 10(6):e0128753,
2015 Jun 2.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-10592 Filed 5-17-18; 8:45 am]
BILLING CODE 4150-31-P
